Gotoh A, Mizuno Y, Takenaka A, Gohji K, Ogawa T, Arakawa S, Kamidono S, Harada K, Nagata H, Hirooka K
Department of Urology, Kobe University School of Medicine.
Nihon Hinyokika Gakkai Zasshi. 1991 Mar;82(3):467-72. doi: 10.5980/jpnjurol1989.82.467.
The clinical significance of serum basic fetoprotein (BFP) in prostatic cancer was investigated together with serum prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA). Investigated in this study were 40 patients with prostatic cancer, ranging in age from 50 to 85 years (mean age: 69.5 years). According to clinical staging, 3 cases (7.5%) had a stage A disease, 10 cases (25.0%) a stage B disease, 7 cases (17.5%) a stage C disease, and 20 cases (50.0%) a stage D disease. The positive rates for serum BFP, PAP, gamma-Sm, and PSA were 60.0, 45.0, 63.6, and 68.4%, respectively, and these rates increased as the stage advanced. The above results suggest that BFP is the most useful marker of the four for monitoring prostatic cancer. In a combination assay of these four markers, 29 (87.9%) of 33 patients with prostatic cancer could be diagnosed by observing an elevated serum level in one of the markers. This suggests that a combination assay of BFP, PAP, gamma-Sm and PSA in patients with prostatic cancer is useful for diagnosis and monitoring of the disease.
我们对血清碱性甲胎蛋白（BFP）在前列腺癌中的临床意义进行了研究，并与血清前列腺酸性磷酸酶（PAP）、γ-精浆蛋白（γ-Sm）和前列腺特异性抗原（PSA）进行了比较。本研究共纳入40例前列腺癌患者，年龄在50至85岁之间（平均年龄：69.5岁）。根据临床分期，3例（7.5%）为A期疾病，10例（25.0%）为B期疾病，7例（17.5%）为C期疾病，20例（50.0%）为D期疾病。血清BFP、PAP、γ-Sm和PSA的阳性率分别为60.0%、45.0%、63.6%和68.4%，且这些比率随着分期的进展而升高。上述结果表明，在这四种标志物中，BFP是监测前列腺癌最有用的标志物。在这四种标志物的联合检测中，33例前列腺癌患者中有29例（87.9%）可通过观察其中一种标志物的血清水平升高来诊断。这表明，对前列腺癌患者进行BFP、PAP、γ-Sm和PSA的联合检测对该疾病的诊断和监测是有用的。
